Old Web
English
Sign In
Acemap
>
Paper
>
Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
2021
Paolo Gisondi
Francesco Loconsole
Paola Raimondo
Roberto Ravasio
Keywords:
moderate to severe
plaque psoriasis
Secukinumab
in patient
Dermatology
Risankizumab
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
29
References
0
Citations
NaN
KQI
[]
map